Edition:
United States

People: Trevena Inc (TRVN.O)

TRVN.O on Nasdaq

2.46USD
22 Sep 2017
Change (% chg)

$-0.04 (-1.60%)
Prev Close
$2.50
Open
$2.50
Day's High
$2.51
Day's Low
$2.41
Volume
236,916
Avg. Vol
522,496
52-wk High
$8.00
52-wk Low
$2.15

Gowen, Maxine 

Dr. Maxine Gowen has served as our President and Chief Executive Officer and as a member of our board of directors since our founding in November 2007. Prior to joining our company, Dr. Gowen was Senior Vice President for the Center of Excellence for External Drug Discovery at GlaxoSmithKline plc, or GSK, where she held a variety of leadership positions during her tenure of 15 years. Before GSK, Dr. Gowen was Senior Lecturer and Head, Bone Cell Biology Group, Department of Bone and Joint Medicine, of the University of Bath, U.K. Dr. Gowen has served as a director of Akebia Therapeutics, Inc. since July 2014. From 2008 until 2012, Dr. Gowen served as a director of Human Genome Sciences, Inc., a public biopharmaceutical company. She received her Ph.D. from the University of Sheffield, U.K., an M.B.A. with academic honors from The Wharton School of the University of Pennsylvania, and a B.Sc. with Honors in Biochemistry from the University of Bristol, U.K.

Basic Compensation

Total Annual Compensation, USD 686,678
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 874,900
Fiscal Year Total, USD 1,561,580

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --